Hep C Treatment Program
IMSS Hep C Treatment to the Caribbean
The IMSS Hepatitis C treatment program encompasses traveling to the Caribbean destination country to fill a prescription for one of two and widely prescribed, proven medications. In compliance with local laws and regulations engagement with a licensed physician is required to receive treatment.
Depending on a person’s individual condition they will be prescribed one of the following two regimens.
Sofosbuvir
Sofosbuvir marketed under the name of Solvaldi®, is a medication used for the treatment of chronic hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir, daclatasvir, or velpatasvir. Cure rates are 30 to 97% depending on the type of hepatitis C virus involved.
Ledvir-Ledipasvir/sofosbuvir
marketed under the trade name HARVONI®, is a medication used to treat chronic hepatitis C virus. It is a combination of ledipasvir and sofosbuvir. Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV) genotypes 1, 4, 5, 6 infections. It is taken daily by mouth for up to 8-24 weeks.
Treatment Program is all inclusive at US $24,500
- Travel & Travel Insurance
- Transfers (transportation to and from airports, hotels, and medical appointments)
- Four & Five Star Resorts - All-Inclusive !!
- Medical Visits with Boarded Physician
- Medication
*Presently, the only known cost-competitive alternatives for the treatment of Hepatitis C, require travel to India, Egypt or Pakistan. Not only do these destinations necessitate long and exhaustive travel, most locations are considered by US patients to encounter too many safety risks.
Hep C Treatment Program Itinerary:
Note – Patient must be able to travel independently without restriction to be accepted into the program.
1. If the candidate has health insurance coverage the Plan Sponsor / Carrier is contacted to determine, to what degree, the IMSS Hep C program is covered and if any modification to the SPD (Summary Plan Design) is warranted. If necessary, assistance is coordinated by IMSS to provide guidance by ERISA analysts to propose any necessary modification to the Plan’s documents allowing the IMSS Hep C program as a Medical Tourism covered procedure.
2. A personalized HIPPA compliant patient portal is set up to receive and send necessary patient medical and program documentation.
3. Medical Documentation includes existing medical doctor visit records, relevant laboratory test results, relevant prescription history and current medications, treatment consents and releases and customs documentation.
4. All participants’ existing medical records are examined and reviewed to determine which participants will be accepted into the program. Acceptance is based on the likelihood a matched regimen is available to the patient’s particular disease. This will increase the likelihood of a successful outcome.
5. Travel Documentation includes a participant’s Passport, Visa and any other documentation required by the destination country. Any documents required will need to be verified as current and valid before travel plans and medical appointments are scheduled. If necessary, assistance will be provided by IMSS in the application for any new documents.
6. A participant receives medication information package for education, as well as, related reference websites.
7. A participant receives temporary international cell phone service (added to the participant's existing cell phone service) to provide emergency contact by phone both in the US and in the destination country. This added service also allows Geo- tracking using HX Global software.
8. An initial 15-minute physician visit is scheduled for patient examination and review of related medical records required to write the medication prescription.
9. The patient takes the prescription to a designated pharmacy to have it filled. As a distributor of the manufacturer, IMSS maintains the chain of custody from the manufacturer to the dispensing pharmacy.
10. A second 15-minute physician visit is scheduled to determine the medication response and review for any possible adverse events.
11. The prescription adherence is electronically tracked and the patient is contacted by a case manager when non-adherence is identified.
12. All medical records concerning a patient’s program participation is sent to the participant’s U.S. treating physician.
Ready to Begin?
Let our consultants help you determine if the IMSS Hep C Treatment Program is right for your organization. Call today to discuss potential
savings, answer human resource and legal questions and any additional questions you may have about offering this global care option.
314-279-3913
